FDA requires strong warnings for opioid analgesics, prescription opioid cough products, and benzodiazepine labeling related to serious risks and death from combined use.

After an extensive review of the latest scientific evidence, the U.S. Food and Drug Administration announced today that it is requiring class-wide changes to drug labeling, including patient information, to help inform health care providers and patients of the serious risks associated with the combined use of certain opioid medications and a class of central nervous system (CNS) depressant drugs called benzodiazepines.

Study Information

FDA News Release

Full Study

https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm518697.htm

Recent news

Gut microbiota's role in the enhancement of type 2 diabetes treatment by a tradi
Effects of probiotic, cinnamon, and synbiotic supplementation on glycemic contro
Antioxidative effects of Cinnamomi cassiae and Rhodiola rosea extracts in liver
Design, synthesis and biological evaluation of cinnamic acid derivatives with sy
Cinnamaldehyde attenuates streptozocin-induced diabetic osteoporosis in a rat mo
Recent news
Gut microbiota's role in the enhancement of type 2 diabetes treatment by a tradi
Effects of probiotic, cinnamon, and synbiotic supplementation on glycemic contro
Antioxidative effects of Cinnamomi cassiae and Rhodiola rosea extracts in liver
Design, synthesis and biological evaluation of cinnamic acid derivatives with sy
Cinnamaldehyde attenuates streptozocin-induced diabetic osteoporosis in a rat mo
Next article Fatty Acid Regulation of Voltage- and Ligand-Gated Ion Channel Function.

Latest Articles

Is Your Immune System Ready for Winter? Antioxidants
Dr. Linda J. Dobberstein, DC, Board Certified in Clinical Nutrition

Is Your Immune System Ready for Winter?

View details
Does Your Protein Supplement Contain Lead? Protein
Dr. Linda J. Dobberstein, DC, Board Certified in Clinical Nutrition

Does Your Protein Supplement Contain Lead?

View details
Next-Generation Gut Support: Introducing the New Super Dophilus Allergies
Dr. Linda J. Dobberstein, DC, Board Certified in Clinical Nutrition

Next-Generation Gut Support: Introducing the New Super Dophilus

View details